Lilly’s triple-hormone obesity drug achieves major weight-loss results but unclear on heart risk

Eli Lilly’s retatrutide (GIP/GLP-1/glucagon triple agonist) met primary endpoints in two Phase 3 TRIUMPH trials, delivering about 21–23% weight loss at 80 weeks with the 12 mg dose vs ~3.2% for placebo (TRIUMPH-2: 20.8%; TRIUMPH-3: 22.6%). However, cardiovascular risk reduction was not clearly demonstrated, and GI side effects were common (diarrhea, nausea) with higher discontinuation rates. Lilly plans FDA submission in Q1 2027 and frames retatrutide as potentially applicable to obesity, knee osteoarthritis pain, and sleep apnea, though analysts warn the market could be niche and tolerability may limit use.